Decode Your Wellbeing: The Zombie Cell Theory of Aging Meets Reality

This story is part of Decode Your Wellbeing, our eight-part guide. Start with the full guide.

Editor’s note. This is a report on published research as of July 19, 2026. It is journalism, not medical advice, and not a recommendation to take any compound. Several drugs named here are prescription medicines or research chemicals. Talk to a physician.

In 2016, scientists at the Mayo Clinic flushed worn-out cells out of aging mice and watched the animals live measurably longer, with healthier hearts and kidneys. It was one of the results that launched a field. A decade later, the biotech company that first tried to turn that discovery into a medicine is quietly winding itself down.

Both facts are true, and together they tell you almost everything about senolytics: the biology is genuinely exciting, and turning it into a treatment for people has been genuinely hard.

What a zombie cell actually is

When a cell suffers enough stress or damage, it can enter a state called senescence. It stops dividing, which is protective, because a damaged cell that cannot multiply cannot become a tumor. But many of these cells refuse to die. They sit in the tissue and secrete a cocktail of inflammatory molecules that scientists call the senescence-associated secretory phenotype, or SASP. In small numbers and for short periods, that signaling is useful. Over decades, as the cells accumulate, it is thought to feed the chronic, low-grade inflammation that tracks with frailty, heart disease, and cognitive decline.

The mouse results that started it

The foundational work came from the lab of Jan van Deursen at the Mayo Clinic. In 2011 and again in a pivotal 2016 paper in Nature, his team used a genetic switch to kill off senescent cells in mice. Naturally aged animals lived longer, developed tumors later, and kept healthier organs. Those findings were dramatic enough to define a new category of anti-aging drug and to spin out companies chasing it.

The one solid human result

The most-studied approach in people combines dasatinib, a leukemia drug, with quercetin, a plant compound. In 2019, Mayo researchers reported that nine patients with diabetic kidney disease who took the pair showed a clear drop in senescent cells in their fat tissue, around 35 percent, along with lower inflammatory markers. It was tiny and had no placebo group, but it was the first direct evidence that a drug can reduce senescent-cell burden in a living person. A separate 2019 pilot in patients with a scarring lung disease reported better physical function on similar treatment.

Where the field actually stands

Beyond that, the human record thins out fast. Fisetin, the most popular natural candidate, has been in a Mayo-run trial for years, but no efficacy results have been published. And the cautionary tale is Unity Biotechnology, the company built to commercialize the mouse discoveries. Its lead drug for knee osteoarthritis failed a Phase 2 trial in 2020, matching placebo. Its pivot to an eye disease drug missed its main goal in 2025, and the company has since said it is exploring a sale or wind-down. The biotech that gave the field its name is, in effect, leaving it.

Not all zombies are villains

The science has also grown more careful in a way that matters. Researchers now stress that senescence is not uniformly bad. Transient senescent cells aid wound healing and embryonic development, and the arrest itself is a brake on cancer. Clearing all of them indiscriminately could do harm. The field is shifting toward targeting only the damaging subsets, which is slower, harder work than the early excitement implied.

So the responsible view in 2026 is that senolytics are a promising research direction, not a proven therapy. No senolytic is approved to slow aging. Some compounds are sold as supplements or obtained as research chemicals, but their dosing and long-term safety for that purpose are unsettled. Meanwhile the levers that reliably lower the body’s senescent and inflammatory load, regular exercise, good sleep, and metabolic health, remain the ones with the broadest human evidence. That is a recurring theme in this series, and it is not a coincidence.

HeadLines Decoded reports on the science of aging. We do not offer medical advice. Talk to a qualified clinician before considering any experimental compound.